Valion Bio, Inc. has received effectiveness for its S-3 registration statement, allowing the company to raise capital through public offerings. This development is crucial for Valion as it seeks to enhance its financial position and support its growth strategies.

Valion Bio, Inc. operates within the pharmaceutical preparations industry, as classified under SIC code 2834. The company is listed on the Nasdaq under the ticker symbol VBIO. It was formerly known as Tivic Health Systems, Inc. and is incorporated in Delaware.

The recent SEC filing indicates that the effectiveness date for the S-3 registration statement is October 20, 2026. This registration allows Valion to offer securities to the public, which can be instrumental in financing its projects and initiatives.

This move may have implications for investors and stakeholders in the pharmaceutical preparations sector. With increased access to capital, Valion could enhance its research and development efforts, potentially leading to new products and innovations.

The filing does not specify what happens next for Valion Bio, Inc. following this effectiveness announcement.

Company Background

Valion Bio, Inc. is incorporated in Delaware and operates its business from San Antonio, Texas. The company was formerly known as Tivic Health Systems, Inc., with a name change that took effect on September 10, 2019. Valion is classified under the pharmaceutical preparations industry with the SIC code 2834, indicating its focus on developing and marketing pharmaceutical products.

Financial Details

The SEC filing indicates that Valion Bio, Inc. has a Central Index Key (CIK) of 0001787740 and a Federal Employer Identification Number (EIN) of 814016391. The company's fiscal year ends on December 31, aligning its financial reporting with the calendar year.

Future Prospects

While the filing confirms the effectiveness of the S-3 registration statement, it does not provide specific details regarding the types of securities Valion intends to offer or the potential projects that may be financed through this capital raise. Investors may be keen to see how the company plans to utilize the funds raised and what new initiatives or products may emerge as a result.